INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE /// EXPLORE NOW INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE ///
June 2 — 5, 2023 Chicago, IL

Booth #2049
Industry Expert Theater #2
Evening Reception
Early access to Tempus One

ASCO® Annual Meeting 2023

Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to share our latest scientific and clinical research findings along with new AI-enabled technology during the 2023 ASCO® Annual Meeting.

Schedule a meeting with us

Get early access to
Tempus One

Schedule time to stop by our booth to get early access to Tempus One: the first AI-enabled clinical assistant that provides access to patient insight directly at your fingertips. The new technology is available anytime, anywhere - on Tempus Hub or the mobile app.

Get early access
Industry Expert Theater Session
June 3, 2023
live session
Kate Sasser, PhD, Chief Scientific Officer (Tempus); Calvin Chao, MD, SVP of Medical Affairs (Tempus); Ezra Cohen, MD, Chief Medical Officer of Oncology (Tempus)

AI-Enabled Precision Medicine is Here: Leveraging insights derived from data to advance cancer care

Join us in the exhibiting hall at McCormick place, as we explore the intersection of real world data, machine learning, and genomic sequencing. We will dive into Tempus’ suite of technologies and NGS platform which work together to rapidly deliver insights that are transforming precision oncology and revolutionizing patient care.

*Not an official event of the 2023 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation. Not CME accredited.

Poster Highlights
June 3, 2023
Abstract/Poster
3123/321
First Author
Stephanie Thiede (Tempus)

Homologous Recombination Deficiency (HRD) in Non-Small Cell Lung Cancer: Genomic Analysis Using an RNA-based HRD Algorithm

Tempus used its RNA-based HRD algorithm to determine HRD positive (HRD+) and HRD negative (HRD-) status among NSCLC patients, and to assess differences in clinical features and genomic landscapes across the two groups. The team found that the NSCLC patients classified as HRD+ by the RNA algorithm represent a unique, molecularly defined subset that has a decreased prevalence of NCCN-driver mutations, with no significant differences in TMB-H or PD-L1 expression. Additionally, 78% of these HRD+ patients did not have any known alterations in HRR genes, indicating this molecularly distinct subgroup may be missed by looking at DNA alterations alone. This study emphasizes the utility of RNA sequencing and suggests that RNA-based HRD testing may provide insight into the biology of NSCLC.

Abstract/Presentation
5034/128
First Author
Brooke Rhead (Tempus)

Genetic Ancestry Associations with Somatic Mutations in a Real-World Cohort of Over 3,000 Prostate Cancer Patients

Abstract/Presentation
5061/155
First Author
Elisa Ledet (Tulane)

Associations Between Androgen-Directed Treatments and AR Mutational Landscapes in the Circulating Tumor DNA of a Real-World Metastatic Prostate Cancer Cohort

Abstract/Presentation
3134/332
First Author
Abdul Rafeh Naqash (University of Oklahoma)

Characterizing the landscape of RING-type E3 ubiquitin transferase altered (RNF43 alt*)* colorectal cancer (CRC) and defining unique subsets with potential therapeutic vulnerabilities in microsatellite instability-high (MSI-H) CRC

live session
Abstract/Poster
10522/155
First Author
Catherine Handy Marshall (Johns Hopkins)

Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers

Tempus leveraged its multimodal real-world database to compare the frequency of CHIP mutations for patients with and without germline HRR mutations in BRCA-associated cancers (breast, ovarian, prostate, and pancreatic), as captured using xT tumor-normal matched testing. The team found that patients with germline BRCA1 mutations had similar or higher levels of CHIP mutations compared to the sporadic group among breast and ovarian cancer types, despite having a lower median age of diagnosis. This indicates that gHRR mutations may influence the frequency of CHIP mutations in BRCA-associated cancer types.

Abstract/Poster
6610/102
First Author
Zachary Rivers, (Tempus)

Molecular diagnostic classification for cancers of unknown primary (CUP): post-testing diagnosis and treatment impact analysis from real-world claims data

The study used claims data from the Komodo Healthcare map to show that a majority of patients with cancers of unknown primary (CUP) receiving the Tempus Tumor Origin (TO) test had their care impacted by the algorithm results. The study was divided into two portions: 483 patients for the diagnosis analysis and 213 for the medication analysis (overlap of 206 patients); and the team observed the following post-TO testing:

  • 49.9% (n=241/483) of patients had a diagnostic code change
  • 63.8% (n=136/213) had a treatment change
  • 41% (n=85/206) had both a code and treatment change

In total, 59.6% (n=292/490) of patients were impacted by the use of the RNA-based TO classifier, demonstrating the potential value RNA sequencing and TO can provide in the treatment of CUP patients.

Abstract/Poster
6595/87
First Author
Brittany McKelvey (Friends of Cancer Research)

Real-world Response Endpoints in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy Across Real-World Datasets

In collaboration with Friends of Cancer Research, Tempus sought to identify what methods may be used to assess chemotherapy response rate within real-world multimodal datasets. The group examined real-world data from 1,380 metastatic NSCLC patients treated with platinum doublet chemotherapy drawn from 7 different multimodal databases and found that the real-world response rates and time to event endpoints calculated for each were relatively consistent.

June 4, 2023
Abstract/Poster
8553/180
First Author
Rachel Minne (University of Wisconsin)

Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer

METex14 NSCLC tumors exhibited differences in measures of several IO biomarkers (TMB, NTB, PD-L1) and showed a distinct somatic landscape compared to non-METex14 NSCLC tumors. These variations in MET-altered NSCLC may impact treatment considerations and require further exploration.

Abstract/Poster
9136/124
First Author
Charu Aggarwal (University of Pennsylvania)

Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status

In this large RWD analysis, Tempus retrospectively analyzed 1,576 advanced NSCLC patients treated with first-line pembrolizumab alone (P) or in combination with chemotherapy (CT + P) and stratified results based on KRAS G12C status. The team noted that KRAS G12C-altered patients with a PD-L1 status of TPS < 1% and < 50% receiving standard CT + P have the shortest survival among all evaluated subgroups and have a high incidence of co-mutations in STK11 and KEAP1. This has implications on optimizing patient selection for KRAS G12C inhibitors that are currently being evaluated in clinical trials.

live session
Abstract
10512
First Author
Ramaswamy Govindan (Washington University)

Germline alterations in patients with lung cancer

This study leveraged the Tempus multimodal real-world database to analyze 11,740 tumors from primary lung cancer patients. The team found infrequent pathogenic/likely pathogenic germline alterations identified through the tumor-normal match feature of the xT test present across different lung cancer subgroups, including for both smokers and non-smokers. This indicates that while lung cancer has not historically been considered for hereditary testing, there may be a subset of lung cancer patients with germline mutations that benefit from testing.

live session
Abstract
10509
First Author
Ali Arafa (University of Minnesota)

Effect of germline mutations shape somatic alteration landscapes in BRCA-associated cancers

Using Tempus’ multimodal real-world database, the team captured how germline mutations could shape the somatic alteration landscape in four BRCA-associated cancers (breast, ovarian, prostate, and pancreatic). Germline alterations in homologous recombination repair genes (gHRR) were detected in 4-6% of patients. The results of this study suggest that gHRR-mutated cancers have distinct genomic landscapes that may influence therapeutic considerations.

June 5, 2023
Abstract/Presentation
3536/236
First Author
Michael H. Storandt (Mayo Clinic)

Genomic landscapes of early-onset versus average-onset colorectal cancer populations

Abstract/Presentation
5061/155
First Author
Fiyinfolu Balogun (Memorial Sloan Kettering)

Microsatellite instability high (MSI-H): A definitive predictive biomarker for immune checkpoint inhibitors (ICI) yet understudied in underrepresented minorities (URM) with gastrointestinal (GI) cancers

Abstract/Presentation
3541/241
First Author
David Hein (University of Texas South Western)

Racial and Genetic Ancestry Associations with Gene Expression Patterns in a Real-World Cohort of Colorectal Cancer Patients

Abstract/Poster
1583/177
First Author
Amol Rao (MemorialCare)

The Tempus TIME Trials Portal Maximizes Clinical Trial Enrollment

The TIME trial network consists of 8,500+ oncologists who work with Tempus to provide clinical trial matching services for hard-to-find and underserved patient populations. The highest-performing clinical TIME sites were those with EMR integrations and/or yearly updates in >50 patients. While such sites constituted roughly 40% of sites, they consented approximately 80% of the total patients. Tempus Link stores both clinical trial documents and patient status updates, which allows for real-time communication between the TIME team and clinical sites to facilitate trial enrollment.

Powered by Tempus Sequencing and/or Multimodal RWD
June 3, 2023
Abstract/Poster
10553/186
First Author
Kenna Noel Koehler

Integrated clinical, pathologic, and genetic data in a racially diverse hereditary breast cancer cohort

Abstract/Poster
3138/336
First Author
Xuanyi Li (Vanderbilt)

Pathway enrichment analysis in tumors with high mutation burdens and interferon-g signature expression: A pan cancer analysis

June 4, 2023
Abstract/Poster
9051/39
First Author
Mo Yang (EMD Serono)

Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting

Abstract/Poster
9034/22
First Author
Jordan Kardos (Gilead)

Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer

Online Poster Presentations
June 2, 2023
Online Only Presentation
e13568
First Author
Leo Posteraro (Tempus)

Time Savings from Integrating Discrete, Genomic Data Into the Electronic Health Record Using the Epic Aura Network

Using Epic's Aura platform, the speed of Tempus EHR integration was improved by 78% to build infrastructure for the bidirectional transfer of discrete genomic data. Dedicated EHR integration resourcing reduced deployment times to as low as 3 weeks.

Online Only Abstract
e15091
First Author
Maryam Lustberg (Yale)

The Genomic Landscape of Adolescent and Young Adult (AYA) Malignancies using DNA and RNA-based Next Generation Sequencing

Online Only Abstract
e12575
First Author
James Chen (Tempus)

Exchanging Genomics Reports Between Pathology Labs and Medical Centers Using the Minimal Clinical Oncology Data Element (mCODE) FHIR Implementation Guide

Online Only Abstract
e12538
First Author
Vincent Perez (Tempus)

FcεRIγ-negative NK cells are associated with improved outcomes in trastuzumab-treated patients

Online Only Abstract
e18892
First Author
Brooke Byrd (CVS Health)

Using Real-World Evidence to Evaluate Broad Panel vs. Sequential Single and Narrow Panel Sequencing in Members with Non-Small Cell Lung Cancer (NSCLC)

Online Only Presentation
e18036
First Author
Mihir Bhayani (Rush)

Association of molecular profiles of head and neck squamous cell carcinoma with heterogeneity across racial/ethnic groups in the United States

Online Only Presentation
e15105
First Author
Eric Vail (Cedars-Sinai Medical Center)

Identification of a novel class of early exon ALK rearrangements across two pan tumor sequencing databases

Online Only Presentation
e17633
First Author
Sameer Talwalkar (Norton Cancer Institute), Mary Gordinier (Norton Healthcare)

Genomic characterization of vulvar squamous cell carcinoma to reveal differential gene expression based on clinical outcome

Online Only Presentation
e21032
First Author
Mo Yang (EMD Serono)

Patient characteristics, treatment patterns, and clinical outcomes among patients with de novo advanced or metastatic (stage IIIB–IV) non-small cell lung cancer in a real-world setting

Online Only Presentation
e21088
First Author
Dina Oksen (Merck KGaA)

Analysis on real-world chemotherapy outcomes in patients (pts) with tyrosine kinase inhibitor (TKI) resistant advanced EGFR-mutant non–small-cell lung cancer (NSCLC) in the United States

Online Only Presentation
e21019
First Author
Nicole Yun (Rush)

RNA sequencing to characterize pathways in EGFR-mutated non-small cell lung cancer

Online Only Presentation
e18563
First Author
Rizvan Azimazade (Alameda Health System)

Next generation sequencing (NGS) testing for cancer patients at a safety NET hospital

Online Only Presentation
e16519
First Author
Michael Glover (Stanford)

Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes

Online Only Presentation
e16538
First Author
Claud Grigg (Levine Cancer Institute)

Association of tumor homologous recombination deficiency (HRD) score with immune checkpoint inhibitor benefit in metastatic clear cell renal cell carcinoma

Schedule a meeting with us

We'll be in touch shortly.